NeuVasQ

Belgium
Gozée, Wallonia, Belgium

Company profile

NeuVasQ company profile

NeuVasQ is developing drugs to restore blood-brain barrier function in acute neurological disorders such as stroke and epilepsy, as well as neurodegenerative diseases such as Alzheimer's. It is based on discoveries about the molecular mechanisms that keep the blood-brain barrier intact (BBB). The BBB regulates the exchange of information between the vascular and central nervous systems (CNS). Increased BBB permeability, whether due to age or injury, plays a role in many neurological conditions by allowing harmful blood substances to enter the CNS. Many neurodegenerative disorders, such as Alzheimer's, as well as a variety of acute neurological conditions, such as stroke and epilepsy, are associated with BBB dysfunction.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2021-01-01, Year

Headquarters

Country code
BE
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
1
Total equity funding
$23.9M
Last funding
Series A / $23.9M / 2021-06-24
Last equity funding
Series A / $23.9M
Investors
1
Lead investors
1
Founders
1
Articles
3

Founders and investors

Founders

Benoit Vanhollebeke

Lead investors

Newton Biocapital

Investors

Newton Biocapital